Free Content

PLAIN LANGUAGE SUMMARIES

Aspirin and NSAID use and keratinocyte cancers

Linked article

Article first published online: 01 Oct 2019
DOI: 10.1111/bjd.18389

Comment on this article

Summary

It is thought that aspirin and other nonsteroidal anti‐inflammatory drugs (NSAIDS) may protect against keratinocyte skin cancers, i.e. squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). However, the evidence for this is scant. The authors, based in Queensland, Australia, studied a group of middle‐aged or elderly Queensland residents obtained from the register of voters (the QSkin study). They compared the incidence of keratinocyte cancers in a three‐year period in individuals who self‐reported taking aspirin or another NSAID regularly, with those who did not. In patients at high risk (such as having a history of previous skin cancer or multiple patches on the skin called actinic lesions) they found that taking aspirin infrequently (less than once a week) was associated with a slightly reduced risk of SCC. Regular use of other NSAIDS (at least once a week) led to a slightly reduced risk of BCCs. In low‐risk patients (no history of skin cancer and fewer than 5 actinic lesions) the authors found no reduced risk from taking aspirin or other NSAIDs. The authors comment that many patients are on low dose aspirin to reduce the risk of heart attacks or strokes, but this may be inadequate to prevent skin cancer. As most patients purchase non‐steroidal drugs over the counter, it was not possible to determine dosage and duration of treatment. They conclude that the protective effect of NSAIDS is slight and only of value in patients at high risk.

Read moreRead more (PDF)

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

13 Nov 2019

Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu

@BrJDermatol

13 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd

@BrJDermatol

13 Nov 2019

RT Dr Katie Farquhar @katiefarquhar: Very interesting article looking at skin cancer trends in transplant recipients from @BrJDermatol https://t.co/ia0PTvQCx9

@BrJDermatol

12 Nov 2019

Why has there been a significant reduction in the incidences of both SCC and BCC in organ transplant recipients over the past two decades? https://t.co/9LZepIh0V0 #SCC #BCC #organtransplant #epidemiology https://t.co/7mFJDPG3ch

@BrJDermatol

12 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: There is a need for more economic studies which look at the costs and effectiveness of two or more eczema treatments. These types of studies help inform how healthcare resources are used. https://t.co/jXK2mF2WQe @BrJDermatol @Wiley_Health @eczemasociety https://t.co/r90pWBEcRK

@BrJDermatol

11 Nov 2019

Join the discussion regarding the definition and clinical implications of palmoplantar pustulosis at https://t.co/rvMFifNM5l #psoriasis #commentary https://t.co/4BQRcTOq2S

Close